2026

President’s Innovation Challenge

Name: Upstatement
Price range: $

Out of 400+ applications, we've selected 180+ PIC semifinalists. These ventures represent all 13 Harvard schools and are one step closer to winning a share of $500,000+ in Bertarelli Foundation funding.

An internal PIC selection committee reviews initial venture applications and selects the semifinalists.

Industry

Program

School

Clear all filters

Absco Therapeutics

AbscoTx injects image-guided therapy into tumors to educate the immune system to fight cancer locally and at metastatic sites.
Bench Agent

Turning scattered lab notes and data into shared memory, knowledge, and insights with an AI lab agent to accelerate research.
EPHIUS Tx

Developing novel therapeutics that block EPH protein overactivity to reverse inflammation and fibrosis in chronic kidney disease.
HarborSite

Developing a next-generation gene insertion platform for the treatment of genetic and age-associated diseases.
Linton Lifesciences

Using 3D bioprinting to create custom arteries for bypass surgery, aiming to replace traditional autologous grafts.
Melia Diagnostics, LLC

Developing quantitative, in-house small-molecule diagnostics for veterinary care, with potential applications in human health.
NanoDEX

Accelerating drug discovery by leveraging nanopore technology to target previously challenging proteins.
NuCyRNA Therapeutics

Redefining RNA-targeting therapeutics, starting in neurodegenerative diseases.
Overture Therapeutics

Creating better, healthier weight-loss intervention therapies for treating obesity and its co-morbidities by targeting emerging biological pathways.
PathCision Medicine

Developing tissue-informed precision therapeutics with superior delivery and efficacy for cancer and other complex diseases.
PieD

Developing an AI-powered wearable photonic device for at-home heart failure monitoring through real-time, multi-biomarker detection.
Procure Bio

Engineering protein nanoparticles for targeted delivery of gene and protein therapeutics, advancing novel treatments for genetic diseases.
Promakhos Therapeutics Inc.

Developing oral, non-immunosuppressive, small molecules to cure chronic inflammatory disorders.
Salience

Enabling high-bandwidth human–AI collaboration by allowing agents to understand user intent beyond text and command-based interactions.
Upaya Health

Reimagining dermatology with plant-based, CBD-driven solutions that reduce inflammation and promote skin wellness.

Out of 400+ applications, we've selected 180+ PIC semifinalists. These ventures represent all 13 Harvard schools and are one step closer to winning a share of $500,000+ in Bertarelli Foundation funding.

An internal PIC selection committee reviews initial venture applications and selects the semifinalists.

Industry

Program

School

Absco Therapeutics

Bench Agent

EPHIUS Tx

HarborSite

Linton Lifesciences

Melia Diagnostics, LLC

NanoDEX

NuCyRNA Therapeutics

Overture Therapeutics

PathCision Medicine

PieD

Procure Bio

Promakhos Therapeutics Inc.

Salience

Upaya Health